These results are important to our understanding of the pathogenesis of ANS dysfunction in patients with epilepsy and have implications for therapeutic interventions targeting BDNF and IGF-1 signaling to correct central autonomic dysfunction and impairment of cerebral autoregulation, particularly in older patients and individuals at high risk for SUDEP. The gene discussed is IGF1; the disease is epilepsy.